Q9CS00

PR
Gene name
Cactin
Protein name
Cactin
Names
Species
Mus musculus (Mouse)
KEGG Pathway
mmu:70312
EC number
Protein Class

Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

1-209 (Predicted disordered autoinhibitory region) PR

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

References

Autoinhibited structure

Activated structure

1 structures for Q9CS00

Entry ID Method Resolution Chain Position Source
AF-Q9CS00-F1 Predicted AlphaFoldDB

28 variants for Q9CS00

Variant ID(s) Position Change Description Diseaes Association Provenance
rs3401524798 110 C>* No EVA
rs3401524822 122 W>* No EVA
rs221244640 122 W>R No EVA
rs3389128152 142 S>F No EVA
rs3401374236 148 S>R No EVA
rs240648472 150 G>R No EVA
rs3401479501 151 T>R No EVA
rs3389120528 152 A>P No EVA
rs3389093829 196 K>* No EVA
rs3413077087 206 K>M No EVA
rs3389122246 208 G>C No EVA
rs3389084452 243 I>N No EVA
rs3389093804 257 R>S No EVA
rs3389059469 263 R>C No EVA
rs3389093783 277 E>V No EVA
rs3389126784 297 E>G No EVA
rs3389122340 299 F>Y No EVA
rs3389091310 356 N>H No EVA
rs3389122251 399 L>H No EVA
rs3389118910 416 V>D No EVA
rs3389116397 441 Q>H No EVA
rs3389118914 476 R>H No EVA
rs219943789 512 A>T No EVA
rs264619683 525 G>R No EVA
rs3389093807 552 E>D No EVA
rs3389113675 674 Q>L No EVA
rs3389118934 683 P>L No EVA
rs3389126773 735 F>L No EVA

No associated diseases with Q9CS00

2 regional properties for Q9CS00

Type Name Position InterPro Accession
domain Splicing factor cactin, central domain 292 - 479 IPR018816
domain Splicing factor Cactin, C-terminal 648 - 772 IPR019134

Functions

Description
EC Number
Subcellular Localization
  • Nucleus
  • Cytoplasm, cytosol
  • Nuclear localization with a speckled expression pattern in some cells
  • Colocalizes with NFKBIL1 in the nucleus (By similarity)
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category No pathway information available

7 GO annotations of cellular component

Name Definition
catalytic step 2 spliceosome A spliceosomal complex that contains three snRNPs, including U5, bound to a splicing intermediate in which the first catalytic cleavage of the 5' splice site has occurred. The precise subunit composition differs significantly from that of the catalytic step 1, or activated, spliceosome, and includes many proteins in addition to those found in the associated snRNPs.
cytoplasm The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures.
cytosol The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes.
nuclear speck A discrete extra-nucleolar subnuclear domain, 20-50 in number, in which splicing factors are seen to be localized by immunofluorescence microscopy.
nucleoplasm That part of the nuclear content other than the chromosomes or the nucleolus.
nucleus A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent.
spliceosomal complex Any of a series of ribonucleoprotein complexes that contain snRNA(s) and small nuclear ribonucleoproteins (snRNPs), and are formed sequentially during the spliceosomal splicing of one or more substrate RNAs, and which also contain the RNA substrate(s) from the initial target RNAs of splicing, the splicing intermediate RNA(s), to the final RNA products. During cis-splicing, the initial target RNA is a single, contiguous RNA transcript, whether mRNA, snoRNA, etc., and the released products are a spliced RNA and an excised intron, generally as a lariat structure. During trans-splicing, there are two initial substrate RNAs, the spliced leader RNA and a pre-mRNA.

No GO annotations of molecular function

Name Definition
No GO annotations for molecular function

15 GO annotations of biological process

Name Definition
cellular response to interleukin-1 Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-1 stimulus.
cellular response to lipopolysaccharide Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipopolysaccharide stimulus; lipopolysaccharide is a major component of the cell wall of gram-negative bacteria.
cellular response to tumor necrosis factor Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a tumor necrosis factor stimulus.
innate immune response Innate immune responses are defense responses mediated by germline encoded components that directly recognize components of potential pathogens.
mRNA cis splicing, via spliceosome The joining together, after removal of an intervening sequence composed of one or more introns, of two segments of the same RNA molecule via spliceosomal catalysis to produce an mRNA composed only of exon sequences that all came from the same primary transcript.
negative regulation of I-kappaB kinase/NF-kappaB signaling Any process that stops, prevents, or reduces the frequency, rate or extent of -kappaB kinase/NF-kappaB signaling.
negative regulation of innate immune response Any process that stops, prevents, or reduces the frequency, rate or extent of the innate immune response.
negative regulation of interferon-beta production Any process that stops, prevents, or reduces the frequency, rate, or extent of interferon-beta production.
negative regulation of interleukin-8 production Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-8 production.
negative regulation of lipopolysaccharide-mediated signaling pathway Any process that stops, prevents, or reduces the frequency, rate or extent of signaling in response to detection of lipopolysaccharide.
negative regulation of NF-kappaB transcription factor activity Any process that stops, prevents, or reduces the frequency, rate or extent of the activity of the transcription factor NF-kappaB.
negative regulation of protein phosphorylation Any process that stops, prevents or reduces the rate of addition of phosphate groups to amino acids within a protein.
negative regulation of toll-like receptor signaling pathway Any process that stops, prevents, or reduces the frequency, rate, or extent of toll-like receptor signaling pathway.
negative regulation of tumor necrosis factor production Any process that stops, prevents, or reduces the frequency, rate, or extent of tumor necrosis factor production.
negative regulation of type I interferon-mediated signaling pathway Any process that decreases the rate, frequency or extent of a type I interferon-mediated signaling pathway.

2 homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
Q8WUQ7 CACTIN Cactin Homo sapiens (Human) PR
G5EG14 cacn-1 Cactin Caenorhabditis elegans PR
10 20 30 40 50 60
MRGAGRQMGR DSRSRSRSVG RRGRKQRSRS RGRSRSRSRS RSRSRSRSRS RSRSHGRSSR
70 80 90 100 110 120
RRREHERRRE RKRRSRGRRS DSEGEQRQKS RRRSQSLRPP RWHSQNQSSC SDSGEERAQG
130 140 150 160 170 180
SWARKGHRRS WSPGSSASSL DSPRRSRSPG TATLALSQQQ SLQERLRLRE ERKQQEELLK
190 200 210 220 230 240
AFETPEEKRA RRLAKKEAKE RKKREKMGWG EEYMGYTNTD NPFGDNNLLG TFIWNKALEK
250 260 270 280 290 300
KGISHLEEKE LKERNKRIQE DNRLELQKVK QLRLEREREK AMREQELELL QREKEAEHFK
310 320 330 340 350 360
TWEEQEDSFH LRQAKLRSKI RIRDGRAKPI DLLAKYISAE DDDLAVEMHE PYTFLNGLTV
370 380 390 400 410 420
ADMEDLLEDI QVYMELEQGK NVDFWRDMTT ITEDEIAKLR KLEASGKGPG ERREGVNASV
430 440 450 460 470 480
SSDVQSVFKG KTYNQLQVIF QGIEGKIRAG GPNLDMGYWE SLLQQLRAHM ARARLRERHQ
490 500 510 520 530 540
DVLRQKLFKL KQEQGVESEP LFPILKSEPS AAHSPEPEER PPSPGTSVDP VEPVEPEEAT
550 560 570 580 590 600
APGEAEGEAE GEAVLMEEDL IQQSLADYDA GRYSPRLLTA HELPLDAHVL EPHEDLQRLQ
610 620 630 640 650 660
LSRQQLQATG DASESAEDIF FRRAREGMGQ DEAQFSVEMP LGGRAYLWAD KYRPRKPRFF
670 680 690 700 710 720
NRVHTGFEWN KYNQTHYDFD NPPPKIVQGY KFNIFYPDLI RKRATPEYFL EACADNRDFA
730 740 750 760 770
ILRFHAGPPY EDIAFKIVSR EWEYSHRHGF RCQFANGIFQ LWFHFKRYRY RR